News
Posts are organized into categories for ease of navigation:
- Algorithm - developments to the interpretation algorithm implemented in Python.
- Announcement - general news related to the Molecular Oncology Almanac.
- Annual newsletters - annual newsletters that recap updates.
- Database - changes and additions to the underlying knowledge base.
- Release - aggregated release notes from GitHub releases (serving as the project changelog).
-
Database release
Added entries:
- (FDA) KRAS p.G12C and sensitivity to adagrasib in combination with cetuximab for patients with colorectal cancer received accelerated approval.
- (FDA) NTRK1/2/3 gene fusions and sensitivity to repotrectinib for patients with solid tumors received accelerated approval.
-
Database release
Added entries:
- (FDA) ALK fusions and sensitivity to alectinib for patients with non-small cell lung cancer.
- (FDA) BRAF p.V600E/K (p.V600 variants), rearrangements, and fusions and sensitivity to tovorafenib for patients with low-grade glioma.
- (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to erlotinib for patients with non-small cell lung cancer.
- (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to gefitinib for patients with non-small cell lung cancer.
-
Algorithm release 0.6.0
This release utilizes the v.2024-04-11 release of the underlying MOAlmanac database and primarily focuses on supporting Python 3.12. It incorporates changes from two pull requests: https://github.com/vanallenlab/moalmanac/pull/18 and https://github.com/vanallenlab/moalmanac/pull/19.
Continue reading -
Database release
Added entries:
- (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with acute lymphoid leukemia.
- (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with chronic myeloid leukemia.
- (FDA) BCR::ABL1 and sensitivity to ponatinib in combination with chemotherapy for patients with acute lymphoid leukemia.
- (FDA) BCR::ABL1 and sensitivity to ponatinib for patients with acute lymphoid leukemia.
-
Database release
Added entries:
- (FDA) ALK fusions and sensitivity to crizotinib for patients with anaplastic large cell lymphoma.
- (FDA) EGFR exon 20 insertions and sensitivity to amivantamab-vmjw in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer.
- (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib in combination with cisplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer.
- (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib for patients with metastatic non-small cell lung cancer.
- (FDA) MET exon 14 splice site and deletion variants (exon 14 skipping) and sensitivity to tepotinib for patients with metastatic non-small cell lung cancer.